News & Updates

In patients with rheumatoid arthritis (RA), high disease-associated central nervous system (CNS) pain activation on functional MRI (fMRI) brain scan may help predict clinical response to TNF inhibitor treatment, as shown in a phase III study.

New research in women with vaginal births has found a significant association between haemoglobin levels immediately after childbirth and the likelihood of developing symptoms of postpartum depression (PPD).

Drug therapy problems (DTPs), such as adverse drug reactions (ADRs), remain highly prevalent in children with acute lymphoblastic leukaemia (ALL), a study has found.

Radiologic imaging of high-risk cutaneous squamous cell carcinoma (sSCC) tumours displays unforeseen results such as local invasion and nodal metastasis, which result in changes in management in nearly half of these cases, reveals a study.

Treatment with abrocitinib or dupilumab results in the restoration of skin barrier function in patients with atopic dermatitis (AD), but these therapies show distinct proteomic impacts, according to a study.

In the treatment of individuals with high-impact chronic pain, scalable cognitive behavioural therapy-based treatments appear to produce modest improvements in pain and related functional/quality-of-life outcomes relative to usual care, according to a study.

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.

Exposure to antibiotics within the first 3 months of life carries a modest increase in the risk of global developmental delays, especially in motor skills, cognitive function, and communication abilities, according to a study.

A recent study has shown 100-percent engagement in care and viral suppression among 25 adolescents and youth with HIV (AYHIV) being treated with long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) during follow-up.